ETFIQData as of Nov 19, 2026. · etfiq.com/funds/ibbDownload PDF

IBB Fact Sheet: iShares Biotechnology ETF

Share
$199.54
close, Nov 20, 2026

Over the year to Nov 19, 2026, IBB returned +23.6% in total and charged 0.44% a year.

1-year total return
+21.7%
to Nov 20, 2026
Expense ratio
0.44%
a year
Net assets
$10.8bn
on Nov 19, 2026
Net flow, last 5 trading days
+$165m
daily basis to Nov 19, 2026

Growth of $10,000, 1 year

IBB $12,355 +23.6% · PBUS $10,892 +8.9% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−5.7%
3 months−6.6%
Year to date+18.3%
1 year+21.7%
3 years+70.4%
5 years+30.7%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
GILEAD SCIENCES9.32%
AMGEN INC8.36%
VERTEX PHARMACEUTICALS7.83%
REGENERON PHARMACEUTICALS6.63%
MODERNA5.28%
ARGENX SE ADR3.79%
NATERA2.83%
BIOGEN2.63%
BEONE MEDICINES AG2.44%
INSMED2.25%

IBB top ten by weight, 51.4% of the fund, of its 245 equity positions, from the holdings published by its issuer for Nov 19, 2026.

Facts

Holds 245 stocks in biotech, 43% of its weight in S&P 500 companies · First traded Feb 12, 2001 · Benchmark Its own holdings, as of Nov 19, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, IBB Fact Sheet: iShares Biotechnology ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/ibb/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/ibb.